相关实验视频
Updated: Jul 6, 2026

Tissue Engineering of the Intestine in a Murine Model
Published on: December 1, 2012
儿科炎性肠病的双重生物或小分子疗法:一个单一的中心体验
Cheng Guo1, Jin Zhou1, Guoli Wang1
1Department of Gastroenterology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, No. 56 Nanlishi Road, Xicheng District, Beijing 100045, China.
双重生物疗法或与小分子药物结合的生物药物在中国的耐药儿科发病性炎症性肠病 (PIBD) 患者中显示出有希望的疗效和安全性. 观察到高率的无类固醇临床缓解,便calprotectin显著减少和最小的不良事件.
科学领域:
- 胃肠病学 胃肠病学
- 儿科医学 儿科医学
- 免疫学 免疫学 免疫学
背景情况:
- 儿科发病的炎症性肠病 (PIBD) 在管理方面提出了独特的挑战.
- 耐火性PIBD通常需要先进的治疗策略.
- 关于中国对PIBD的双重生物疗法的数据有限.
研究的目的:
- 评估双重生物疗法或生物药物和小分子药物的组合疗法的疗效和安全性.
- 评估中国不耐药PIBD患者的治疗结果.
主要方法:
- 对临床,实验室,内镜和超声波数据的回顾性分析.
- 包括接受双生物或生物加小分子治疗的PIBD患者.
- 监测无类固醇临床缓解和不良事件.
主要成果:
- 在520名儿童中,有12名儿童 (2.3%) 患有耐火性PIBD,并接受了双重生物疗法.
- 实现了高的无类固醇临床缓解率:91.2%在3个月,100%在6个月,100%在12个月.
- 在12个月内观察到便中位数calprotectin水平的显著降低;一名患者报告轻度,短暂的氨基转移酶升高.
结论:
- 双生物或小分子疗法在耐火PIBD中显示出潜在的有效性和安全性.
- 这种治疗方法为中国的复杂儿科IBD病例的管理提供了可行的选择.
更多相关视频
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
09:44Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease III: Crohn's Disease